江西医药
江西醫藥
강서의약
JIANGXI MEDICAL JOURNAL
2015年
1期
16-19
,共4页
万红英%刘侃%谢斌%魏颖%陈伟涛
萬紅英%劉侃%謝斌%魏穎%陳偉濤
만홍영%류간%사빈%위영%진위도
卵巢肿瘤%WT1%Bcl-2%Ki-67%免疫组化
卵巢腫瘤%WT1%Bcl-2%Ki-67%免疫組化
란소종류%WT1%Bcl-2%Ki-67%면역조화
Ovarian neoplasms%WT1%Bcl-2%ki-67%immunohistochemistry
目的:探讨上皮性卵巢癌组织中WT1、Bcl-2、Ki-67蛋白的表达及其相关性。方法采用免疫组化方法检测62例上皮性卵巢癌组织及10例正常卵巢组织中WT1、Bcl-2、Ki-67蛋白的表达情况。结果⑴10例正常卵巢组织中WT1、Ki-67蛋白均无阳性表达、Bcl-2蛋白1例阳性表达;62例上皮性卵巢癌中WT1、Bcl-2、Ki-67阳性蛋白表达率分别为80.64%(50/62)、53.23%(33/62)、82.26%(51/62)。⑵上皮性卵巢癌组织中WT1、Bcl-2、Ki-67蛋白的表达率高于正常组织(P<0.05);WT1、Ki-67蛋白阳性表达与组织学分级和临床病理分期相关(P<0.05),Bcl-2蛋白阳性表达与组织学分级和临床病理分期不相关(P>0.05)。⑶WT1蛋白表达与Bcl-2蛋白的表达正相关(r=0.463,P<0.05),WT1蛋白与Ki-67蛋白, Ki-67蛋白与Bcl-2蛋白表达之间无相关性(r=0.012、r=0.120、P>0.05)。结论 WT1、Bcl-2、Ki-67蛋白表达在上皮性卵巢癌的发生发展过程中起重要作用,WT1可能通过上调Bcl-2抑制细胞凋亡促使卵巢癌的发生。
目的:探討上皮性卵巢癌組織中WT1、Bcl-2、Ki-67蛋白的錶達及其相關性。方法採用免疫組化方法檢測62例上皮性卵巢癌組織及10例正常卵巢組織中WT1、Bcl-2、Ki-67蛋白的錶達情況。結果⑴10例正常卵巢組織中WT1、Ki-67蛋白均無暘性錶達、Bcl-2蛋白1例暘性錶達;62例上皮性卵巢癌中WT1、Bcl-2、Ki-67暘性蛋白錶達率分彆為80.64%(50/62)、53.23%(33/62)、82.26%(51/62)。⑵上皮性卵巢癌組織中WT1、Bcl-2、Ki-67蛋白的錶達率高于正常組織(P<0.05);WT1、Ki-67蛋白暘性錶達與組織學分級和臨床病理分期相關(P<0.05),Bcl-2蛋白暘性錶達與組織學分級和臨床病理分期不相關(P>0.05)。⑶WT1蛋白錶達與Bcl-2蛋白的錶達正相關(r=0.463,P<0.05),WT1蛋白與Ki-67蛋白, Ki-67蛋白與Bcl-2蛋白錶達之間無相關性(r=0.012、r=0.120、P>0.05)。結論 WT1、Bcl-2、Ki-67蛋白錶達在上皮性卵巢癌的髮生髮展過程中起重要作用,WT1可能通過上調Bcl-2抑製細胞凋亡促使卵巢癌的髮生。
목적:탐토상피성란소암조직중WT1、Bcl-2、Ki-67단백적표체급기상관성。방법채용면역조화방법검측62례상피성란소암조직급10례정상란소조직중WT1、Bcl-2、Ki-67단백적표체정황。결과⑴10례정상란소조직중WT1、Ki-67단백균무양성표체、Bcl-2단백1례양성표체;62례상피성란소암중WT1、Bcl-2、Ki-67양성단백표체솔분별위80.64%(50/62)、53.23%(33/62)、82.26%(51/62)。⑵상피성란소암조직중WT1、Bcl-2、Ki-67단백적표체솔고우정상조직(P<0.05);WT1、Ki-67단백양성표체여조직학분급화림상병리분기상관(P<0.05),Bcl-2단백양성표체여조직학분급화림상병리분기불상관(P>0.05)。⑶WT1단백표체여Bcl-2단백적표체정상관(r=0.463,P<0.05),WT1단백여Ki-67단백, Ki-67단백여Bcl-2단백표체지간무상관성(r=0.012、r=0.120、P>0.05)。결론 WT1、Bcl-2、Ki-67단백표체재상피성란소암적발생발전과정중기중요작용,WT1가능통과상조Bcl-2억제세포조망촉사란소암적발생。
Objective To assess the expression of WT1,Bcl-2,Ki-67 in epithelial ovarian carcinoma and to analyze the cor-relation of the expression level of WT1,Bcl-2 and Ki-67,protein. Methods Consecutive sections from 62 cases of ovarian cancer and 10 normal ovarian tissues were assessed immunohistochemically for expression of WT1 ,Bcl-2 and Ki-67 protein. Results ⑴WT1 and ki-67 proteins were not detectable in normal ovarian tissues. Positive expression of Bcl-2 protein was observed in 1 (10%) of 10 normal ovarian tissues. Positive expressions of WT1,Bcl-2 and Ki-67 proteins were 80.64%(50/62),53.23%(33/62) and 82.26%(51/62) in ovarian cancer respectively. ⑵The expression of WT1,Bcl-2 and Ki-67 protein in ovarian cancer was sig-nificantly higher than that in normal ovarian tissues (P<0.05). The expressions of WT1,Bcl-2 and ki-67 protein were respectively related to histological grade and FIGO stage(P<0.05). The expressions of Bl-2 protein was not related to histological grade and FI-GO stage(P>0.05).⑶A significantly positive relationship was observed between WT1 and Bcl-2 protein expression in primary ep-ithelial ovarian cancer(r=0.463,P<0.05).There was no correlation beween the expressions of WT1 and ki-67,Bcl-2 and ki-67 pro-teins in epithelial ovarian cancer (r=0.012、r=0.120,P>0.05). Conclusion These results suggest that WT1 and ki-67 may be in-volved in the occurrence and development of ovarian cancer. WT1 by upregulating Bcl-2 inhibits apoptosis promote ovarian can-cer.